CRISPR Gene-Editing Advances Lead to Significant Cholesterol Reductions
TL;DR Summary
Crispr and Intellia stocks surged following promising updates on their gene-editing therapies, with Crispr showing potential for a one-time cholesterol treatment and Intellia demonstrating a near-cure for hereditary angioedema, leading to significant stock gains despite recent setbacks in the sector.
- Why These Two Gene-Editing Stocks Just Surged Investor's Business Daily
- CRISPR gene-editing works to reduce high cholesterol in a new study NPR
- Harmful cholesterol levels cut in half with one-time gene editing drug in early trial NBC News
- Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely Lower Cholesterol and Triglycerides Cleveland Clinic Newsroom
- CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
1 min
vs 2 min read
Condensed
86%
283 → 40 words
Want the full story? Read the original article
Read on Investor's Business Daily